Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 7, 2013; 19(17): 2676-2682
Published online May 7, 2013. doi: 10.3748/wjg.v19.i17.2676
Published online May 7, 2013. doi: 10.3748/wjg.v19.i17.2676
Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients
Kumi Ishida, Takuya Inoue, Kaori Fujiwara, Taisuke Sakanaka, Ken Narabayashi, Sadaharu Nouda, Toshihiko Okada, Kazuki Kakimoto, Takanori Kuramoto, Ken Kawakami, Yosuke Abe, Toshihisa Takeuchi, Mitsuyuki Murano, Satoshi Tokioka, Eiji Umegaki, Kazuhide Higuchi, the Second Department of Internal Medicine, Osaka Medical College, Takatsuki City, Osaka 569-8686, Japan
Author contributions: Ishida K and Inoue T performed data compilation, analysis, statistical analysis and manuscript preparation; Fujiwara K, Sakanaka T, Narabayashi K, Nouda S, Okada T, Kakimoto K, Kuramoto T, Kawakami K, and Abe Y has performed the adalimumab/adalimumab + azathioprine treatment; Takeuchi T, Murano M, Tokioka S, and Umegaki E assisted in the analysis and interpretation of data; Higuchi K and Umegaki E revised this manuscript.
Correspondence to: Takuya Inoue, MD, PhD, the Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigakumachi, Takatsuki City, Osaka 569-8686, Japan. ureuretakuwan@yahoo.co.jp
Telephone: +81-72-6831221 Fax: +81-72-6846532
Received: December 20, 2012
Revised: January 17, 2013
Accepted: February 8, 2013
Published online: May 7, 2013
Processing time: 137 Days and 22 Hours
Revised: January 17, 2013
Accepted: February 8, 2013
Published online: May 7, 2013
Processing time: 137 Days and 22 Hours
Core Tip
Core tip: In this study, the authors found that adalimumab (ADA) treatment with concomitant azathioprine usage significantly suppressed the Crohn’s disease activity index and increased the remission rate at 24 wk after the initiation of therapy, compared with ADA treatment alone.